Caspase inhibitors: A pharmaceutical industry perspective

被引：70

作者：

Linton, SD ^{[1
]}

机构：

[1] Idun Pharmaceut, San Diego, CA 92121 USA

来源：

CURRENT TOPICS IN MEDICINAL CHEMISTRY | 2005年 / 5卷 / 16期

关键词：

caspase inhibitor; apoptosis; ICE; VX-740; VX-765; IDN-6556; alpha-fas-induced liver model; Jurkat; peptidomimetics;

D O I：

10.2174/156802605775009720

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Caspase inhibition has been demonstrated to be therapeutically effective in moderating excessive programmed cell death, or apoptosis. Publications detailing programs in the pharmaceutical industry have been more frequent in recent years, ranging from SAR Studies to clinically relevant animal models of disease. A summary of the work published in this exciting new area is presented, outlining the broad applicability of this fundamental cellular mechanism across several disease indications. This area of research has matured to the level of advancing compounds into clinical trials: VX-740 (Pralnacasan) and VX-765 as anti-inflammatory agents, and IDN-6556, a pan-caspase inhibitor as an anti-apoptotic agent.

引用

页码：1697 / 1716

页数：20

共 66 条

[31] A broad-spectrum caspase inhibitor blocks concanavalin A-induced hepatitis in mice [J].

Kim, KM ;

Kim, YM ;

Park, M ;

Park, K ;

Chang, HK ;

Park, TK ;

Chung, HH ;

Kang, CY .

CLINICAL IMMUNOLOGY, 2000, 97 (03) :221-233

[32] Thiol-dependent enzymes and their inhibitors: A review [J].

Leung-Toung, R ;

Li, WR ;

Tam, TF ;

Karimian, K .

CURRENT MEDICINAL CHEMISTRY, 2002, 9 (09) :979-1002

[33] Oxamyl dipeptide caspase inhibitors developed for the treatment of stroke [J].

Linton, SD ;

Aja, T ;

Allegrini, PR ;

Deckwerth, TL ;

Diaz, JL ;

Hengerer, B ;

Herrmann, J ;

Jahangiri, KG ;

Kallen, J ;

Karanewsky, DS ;

Meduna, SP ;

Nalley, K ;

Robinson, ED ;

Roggo, S ;

Rovelli, G ;

Sauter, A ;

Sayers, RO ;

Schmitz, A ;

Smidt, R ;

Ternansky, RJ ;

Tomaselli, KJ ;

Ullman, BR ;

Wiessner, C ;

Wu, JC .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2004, 14 (10) :2685-2691

[34] Acyl Dipeptides as reversible caspase inhibitors. Part 2: Further optimization [J].

Linton, SD ;

Karanewsky, DS ;

Ternansky, RJ ;

Chen, N ;

Guo, M ;

Jahangiri, KG ;

Kalish, VJ ;

Meduna, SP ;

Robinson, ED ;

Ullman, BR ;

Wu, JC ;

Pham, B ;

Kodandapani, L ;

Smidt, R ;

Diaz, JL ;

Fritz, LC ;

von Krosigk, U ;

Roggo, S ;

Schmitz, A ;

Tomaselli, KJ .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2002, 12 (20) :2973-2975

[35] Acyl Dipeptides as reversible caspase inhibitors. Part 1: Initial lead optimization [J].

Linton, SD ;

Karanewsky, DS ;

Ternansky, RJ ;

Wu, JC ;

Pham, B ;

Kodandapani, L ;

Smidt, R ;

Diaz, JL ;

Fritz, LC ;

Tomaselli, KJ .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2002, 12 (20) :2969-2971

[36] The interleukin-1β-converting enzyme inhibitor pralnacasan reduces dextran sulfate sodium-induced murine colitis and T helper 1 T-cell activation [J].

Loher, F ;

Bauer, C ;

Landauer, N ;

Schmall, K ;

Siegmund, B ;

Lehr, HA ;

Dauer, M ;

Schoenharting, M ;

Endres, S ;

Eigler, A .

JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2004, 308 (02) :583-590

[37] Proinflammatory mediators and osteoarthritis [J].

Martel-Pelletier, J .

OSTEOARTHRITIS AND CARTILAGE, 1999, 7 (03) :315-316

[38] A caspase active site probe reveals high fractional inhibition needed to block DNA fragmentation [J].

Méthot, N ;

Vaillancourt, JP ;

Huang, JQ ;

Colucci, J ;

Han, YX ;

Ménard, S ;

Zamboni, R ;

Toulmond, S ;

Nicholson, DW ;

Roy, S .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2004, 279 (27) :27905-27914

[39] Differential efficacy of caspase inhibitors on apoptosis markers during sepsis in rats and implication for fractional inhibition requirements for therapeutics [J].

Méthot, N ;

Huang, JQ ;

Coulombe, N ;

Vaillancourt, JP ;

Rasper, D ;

Tam, J ;

Han, YX ;

Colucci, J ;

Zamboni, R ;

Xanthoudakis, S ;

Toulmond, S ;

Nicholson, DW ;

Roy, S .

JOURNAL OF EXPERIMENTAL MEDICINE, 2004, 199 (02) :199-207

[40] LPS challenge in D-galactosamine-sensitized mice accounts for caspase-dependent fulminant hepatitis, not for septic shock [J].

Mignon, A ;

Rouquet, N ;

Fabre, M ;

Martin, S ;

Pagès, JC ;

Dhainaut, JF ;

Kahn, A ;

Briand, P ;

Joulin, V .

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1999, 159 (04) :1308-1315

← 1 2 3 4 5 6 7 →